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While it is increasingly recognized that three-dimensional (3D) cell culture models recapitulate drug
responses of human cancers with more fidelity than monolayer cultures, a lack of quantitative analysis
methods limit their implementation for reliable and routine assessment of emerging therapies. Here, we
introduce an approach based on computational analysis of fluorescence image data to provide high-content
readouts of dose-dependent cytotoxicity, growth inhibition, treatment-induced architectural changes and
size-dependent response in 3D tumour models. We demonstrate this approach in adherent 3D ovarian and
pancreaticmultiwell extracellularmatrix tumour overlays subjected to a panel of clinically relevant cytotoxic
modalities and appropriately designed controls for reliable quantification of fluorescence signal. This
streamlined methodology reads out the high density of information embedded in 3D culture systems, while
maintaining a level of speed and efficiency traditionally achieved with global colorimetric reporters in order
to facilitate broader implementation of 3D tumour models in therapeutic screening.
T
he attrition rates for preclinical development of oncology therapeutics are particularly dismal due to a
complex set of factors which includes 1) the failure of pre-clinical models to recapitulate determinants of
in vivo treatment response, and 2) the limited ability of available assays to extract treatment-specific data
integral to the complexities of therapeutic responses1–3. Three-dimensional (3D) tumour models have been
shown to restore crucial stromal interactions which are missing in the more commonly used 2D cell culture
and that influence tumour organization and architecture4–8, as well as therapeutic response9,10, multicellular
resistance (MCR)11,12, drug penetration13,14, hypoxia15,16, and anti-apoptotic signaling17. However, such sophist-
icated models can only have an impact on therapeutic guidance if they are accompanied by robust quantitative
assays, not only for cell viability but also for providing mechanistic insights related to the outcomes. While
numerous assays for drug discovery exist18, they are generally not developed for use in 3D systems and are often
inherently unsuitable. For example, colorimetric conversion products have been noted to bind to extracellular
matrix (ECM)19 and traditional colorimetric cytotoxicity assays reduce treatment response to a single number
reflecting a biochemical event that has been equated to cell viability (e.g. tetrazolium salt conversion20). Such
approaches fail to provide insight into the spatial patterns of response within colonies, morphological or struc-
tural effects of drug response, or how overall culture viability may be obscuring the status of sub-populations that
are resistant or partially responsive. Hence, the full benefit of implementing 3D tumour models in therapeutic
development has yet to be realized for lack of analytical methods that describe the very aspects of treatment
outcome that these systems restore.
Motivated by these factors, we introduce a new platform for quantitative in situ treatment assessment
(qVISTA) in 3D tumour models based on computational analysis of information-dense biological image datasets
(bioimage-informatics)21,22. This methodology provides software end-users with multiple levels of complexity in
output content, from rapidly-interpreted dose response relationships to higher content quantitative insights into
treatment-dependent architectural changes, spatial patterns of cytotoxicity within fields of multicellular struc-
tures, and statistical analysis of nodule-by-nodule size-dependent viability. The approach introduced here is
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cognizant of tradeoffs between optical resolution, data sampling
(statistics), depth of field, and widespread usability (instrumentation
requirement). Specifically, it is optimized for interpretation of fluor-
escent signals for disease-specific 3D tumour micronodules that are
sufficiently small that thousands can be imaged simultaneously with
little or no optical bias from widefield integration of signal along the
optical axis of each object. At the core of our methodology is the
premise that the copious numerical readouts gleaned from seg-
mentation and interpretation of fluorescence signals in these image
datasets can be converted into usable information to classify treat-
ment effects comprehensively, without sacrificing the throughput of
traditional screening approaches. It is hoped that this comprehensive
treatment-assessment methodology will have significant impact in
facilitating more sophisticated implementation of 3D cell culture
models in preclinical screening by providing a level of content and
biological relevance impossible with existing assays inmonolayer cell
culture in order to focus therapeutic targets and strategies before
costly and tedious testing in animal models.
Using two different cell lines and as depicted in Figure 1, we adopt
an ECM overlay method pioneered originally for 3D breast cancer
models23, and developed in previous studies by us to model micro-
metastatic ovarian cancer19,24. This system leads to the formation of
adherent multicellular 3D acini in approximately the same focal
plane atop a laminin-rich ECM bed, implemented here in glass-bot-
tom multiwell imaging plates for automated microscopy. The 3D
nodules resultant from restoration of ECM signaling5,8, are hetero-
geneous in size24, in contrast to other 3D spheroid methods, such as
rotary or hanging drop cultures10, in which cells are driven to ag-
gregate into uniformly sized spheroids due to lack of an appropriate
substrate to adhere to. Although the latter processes are also bio-
logically relevant, it is the adherent tumour populations character-
istic of advanced metastatic disease that are more likely to be
managed with medical oncology, which are the focus of therapeutic
evaluation herein. The heterogeneity in 3D structures formed via
ECM overlay is validated here by endoscopic imaging of in vivo
tumours in orthotopic xenografts derived from the same cells
(OVCAR-5).
We utilize the methods introduced here to quantify patterns of
cytotoxic response in two disease systems, 3D ovarian and pancreatic
tumourmodels, subject to a panel of five clinically-relevant cytotoxic
interventions. These treatments represent contrasting mechanisms
of action, and as shown here, varying patterns of size-dependent,
structural, heterogeneous induction of cell death and/or growth
inhibition. Carboplatin is a platinum-based agent which coordinates
permanently to DNA25, paclitaxel acts on cytoskeletal tubulin to
induce defects in mitotic spindle assembly26,27, etoposide is a topoi-
somerase II inhibitor which induces DNA strand breakage by pre-
venting re-ligation28, gemcitabine is a pyrimidine nucleoside analog
which interrupts cell division by replacing cytidine during DNA
replication29, and PDT, with the photosensitizer verteporfin, induces
apoptosis by localized generation of singlet oxygen to damage
anti-apoptotic Bcl-family proteins and trigger direct release of cyto-
chrome c30,31. Therapeutic agents are probed in disease models rel-
evant to their clinical implementation. For example, response to
carboplatin and paclitaxel, used in clinical management of advanced
ovarian cancer32 are examined in a 3D ovarian tumour model, while
gemcitabine, which is the standard agent for palliative care of meta-
static pancreatic cancer33, is examined in 3D culture models of that
disease. In the former, the importance of providing a systematic
approach to analyse size-dependent response is underscored by clin-
ical reports that the size of residual disease is one of the most import-
ant prognostic indicators of treatment outcome for this often-lethal
gynecologic malignancy34–37. But in addition to demonstrating the
utility of the qVISTA methodology, the high-content analysis of
response undertaken here could have significance in providing cor-
relations between cell death and tumour structure. We present the
case that elucidating the relationship between cell death and tissue
organization may also provide a powerful tool to identify synergistic
combinations of therapies analyzed herein, such as carboplatin/
paclitaxel32 and PDT/carboplatin19 combinations for treatment of
advanced ovarian cancer.
Results
Rescaling of vital dye fluorescent signals to provide a ratiometric
dose-response metric. We first examined overall dose response to
classic cytotoxic drugs in 3D ovarian micronodules to establish a
viability metric combining the signals from two fluorescent re-
porters. Cultures prepared by overlay of OVCAR5 cells on growth
factor reduced (GFR) Matrigel in multiwell plates were allowed to
form heterogeneous 3D acini consisting of tens to hundreds of cells,
as previously characterized19,24.
Cultures were assigned into control (no treatment, NT, and total
killing, TK) and treatment groups for administration of paclitaxel,
carboplatin, etoposide or PDT. In Figure 2a, representative merged
Figure 1 | A simplified schematic flow chart of imaging-based quantitative in situ treatment assessment (qVISTA) in 3D cell culture. (This figure was
prepared in Adobe IllustratorH software by MD Glidden, JP Celli and I Rizvi). A detailed breakdown of the image processing (Step 4) is provided in
Supplemental Figure 1.
www.nature.com/scientificreports
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multichannel images of calcein and ethidium bromide stained
cultures (green and red respectively) obtained at low magnification
are shown for a range of paclitaxel doses. Images from each well are
obtained using an automated scanning stage. On a laser scanning
confocal system one can obtain 96 spatial fields (at 512 by 512 reso-
lution), with 3 channels per field (1 brightfield and 2 fluorescence
channels) in approximately 25 minutes, or less than half this time for
widefield illumination imaged onto a CCD chip. In this manner,
large fluorescence image sets containing spatially resolved images
of esterase activity (cleavage of calcein AM) and membrane per-
meability (intercalation of ethidium bromide), in thousands of
labeled nodules for each treatment condition, are rapidly obtained.
Average background-corrected esterase activity in 3D cultures
decreases with increasing cytotoxic doses while the membrane per-
meabilization increases, as expected (Figure 2b).
To correct for incompatible baseline fluorescent signals and scal-
ing from separate reporters, a scaling factor, w, which establishes
internally consistent ‘‘live’’ and ‘‘dead’’ signals is based on the NT
and TK controls for each experiment. The TK control (fixed and
permeabilized), establishes a lower limit of esterase activity with a
high degree ethidium bromide intercalation, in otherwise identically
prepared cultures and imaging conditions, (analogous to a ‘‘blank’’
group). The values of w for the data shown in Figure 2b are 1.09, 1.04,
2.39, and 1.13 for paclitaxel, carboplatin, etoposide, and verteporfin
PDT, respectively. The rescaled values (Figure 2b, lower panels) are
then appropriately combined into a single metric where viability is
interpreted as the quotient of live to total fluorescent signal (the sum
of live and rescaled dead signals). Even with this effort to rescale in a
manner is not therapeutic-dependent, the dynamic range of the sig-
nal from intercalated ethidium bromide may vary due to treatment
dependent effects. For example the ethidium bromide signal at
exceptionally high carboplatin doses is higher than that of the TK
control possibly due to dye binding or optical effects of treatment-
induced DNA damage, hence the rescaled calcein signal appears
relative flat when plotted on the same scale as in Figure 2B even
though it decreases significantly in a dose-dependent manner.
Overall this metric provides a simple and rapid means for reporting
fractional lethal doses (LD), which is validated here by counting of
trypan blue excluding cells (Supplemental Figure 2).
As an imaging-based approach, this methodology also generates
viability statistics for all individual nodules imaged in each set of
multichannel images. The viability readout is mapped to each seg-
mented region (nodule) to quantify heterogeneity in treatment res-
ponse. As shown in Figure 2c, with increasing cytotoxic dose, the
distribution of viabilities shifts to the left as expected with increasing
cell death. For the data shown here for paclitaxel-treated cultures the
viability distribution for each dose is relatively compact and fits to a
single Gaussian mode with a standard deviation of 0.11 at the LD80
dose. When the viability distributions for equivalent LD80 doses of
paclitaxel and carboplatin are overlaid (Figure 2d) it is clear that
there is a broader viability spectrum exhibited by the latter. With a
wide distribution of viability to 80–90% viable and a small shoulder
of completely killed nodules (0–10% viable) at the left side of the
distribution the carboplatin distribution has a far more heterogen-
eous response with a width (standard deviation) of 0.20.
High-content quantification of viabilities in large distributions of
individual micronodules reports differential size-dependent
response. To establish that heterogeneity in nodule size is reflec-
tive of in vivo growth behavior, the same cells were implanted into
mice, as previously described for amurine ovarian xenograftmodel38,
and imaged using a high-resolution fluorescence microendoscopy
approach previously established by us39. As shown in Figure 3, the
bi-modal size distribution of nodules overlaid on extracellularmatrix
resembles the heterogeneity in size of nodular implants on peritoneal
surfaces in vivo. In 3D culture data, to co-register size and cytotoxic
response data, segmented regions are mapped to readouts of size,
reported as volume (V) from an ellipsoid approximation, estimated
number of cells (N), equivalent diameter (deq), major andminor axis
lengths, eccentricity (e), and spatial position (x and y- coordinates) in
addition to calcein and scaled ethidium bromide fluorescence signals
and viability, of each nodule in each field for each treatment group,
totaling several thousand for each multi-well plate imaged. A trun-
cated representation of these readouts is shown for a small sub-
region of a single paclitaxel-treated well in a 96-well plate is shown
in Figure 3b. From this larger numerical dataset, size-viability scatter
plots are shown in Figure 3c, in which each data point indicates the
volume (in mm3, horizontal axis) and viability (vertical axis) for a
given nodule. In general, the densest regions of the scatter shift
toward lower positions on the vertical axis as expected with in-
creasing cytotoxic dose, and consistent with the overall average
values (for non-segmented full image fields) in Figure 2.While pacli-
taxel therapy induces cytotoxicity nearly uniformly over nodule size,
carboplatin and etoposide, even at extremely high doses, show a
significant proportion of larger nodules that remain viable with,
especially for carboplatin, a dense clustering of completely non-
viable nodules in the smallest size range. This suggests a size-
dependent response in which smaller nodules are more sensitive to
treatment than larger nodules, which is typical of clinical treatment
response37. The large spread in viability of nodules exposed to
etoposide across all sizes at the ,LD50 dose suggests that there is
a high degree of heterogeneity with populations resistant to this
agent. PDT treatment using the photosensitizer verteporfin also
exhibits a high degree of heterogeneity, manifested in particular by
the large vertical smear of points at small sizes (less than,10 cells),
with a size-dependent trend for larger nodules.
To verify that quantification of size-dependent effects are not
skewed by optical bias at the relevant wavelengths, we evaluated
the scaling relationship between the integrated fluorescence signal
(for each channel from each nodule) versus nodule volume (Supple-
mental Figure 3). The linear scaling over the majority of data (.85%
for the calcein channel) indicates that signal attenuation due to tissue
optics effects become significant only for the very largest nodules,
which are also the most problematic for volume estimation by the
ellipsoid approximation applied here. Here we examine these effects
in the calcein channel, which requires shorter wavelength excitation
that is more highly scattered (relative to the ethidium bromide
excitation light). Importantly, the validity of fluorescence quantifica-
tion over a wide range of nodule sizes is further established by the
strong agreement between the average viability calculated from
fluorescence and manual counting of cells (Supplemental Figure 2).
Quantification of architectural changes following cytotoxic inter-
vention reveals treatment and dose-dependent nodular disrup-
tion. The ability to place treatment response in the context of
nodule size raises the question of the extent to which treatments
induce changes in the size distribution by breakup or ‘‘unpacking’’
of multicellular nodules. In high resolution confocal images of 3D
nodules stained with vital dyes following carboplatin or verteporfin
photodynamic therapy (PDT), in contrast to no treatment controls
(Figure 4a), the presence of a number of detached single cells around
the periphery of a large nodular core suggest that the latter therapy
causes large (.200 mm) multicellular nodules to disassociate, and
break down into smaller clusters of cells. Informed by a previous
characterization study24, 3D micronodules reproducibly exhibit
distinct log-normal size modes described by a bimodal Gaussian f
5 f1 1 f2. We quantify the extent to which treatment-induced
disruption causes shifts in the proportion of nodules in the mode
corresponding to larger sizes (f2) to smaller sizes (f1). As seen in
Figure 4b, there is a marked dichotomy in the ability of different
therapeutics to induce this size-distribution shift, with pronounced
effects from vertporfin-PDT and paclitaxel treatments, but no shift
www.nature.com/scientificreports
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toward smaller sizes following etoposide or carboplatin treatments.
We describe the extent of this shift as disruption fraction, or Dfrac, a
value which ranges from 21 to 1. In (Figure 4c), dose-dependent
Dfrac is reported relative to the extent of cytotoxic lethality for
selected doses (LD20, LD50, etc) of each agent. Dfrac increases in a
sharply dose-dependent manner for verteporfin PDT treatments,
while carboplatin treatment suppresses viability at very high doses
with no significant architectural disruption. Etoposide treatment
displays a flat Dfrac curve, while paclitaxel induces a marked nodu-
lar disaggregation, it is seen only at higher lethal doses relative to
PDT. A byproduct of the definition of Dfrac, is that negative values
indicate a higher proportion of large (non-disrupted) nodules in
Figure 2 | A viability metric reports overall dose response and heterogeneity based on relative esterase activity and membrane permeability. In (a),
representative thumbnails from merged images of esterase-cleaved calcein AM (green) and intercalated ethidium bromide (red) in ovarian cancer 3D
overlays for (left to right), no treatment (NT) and total killing (TK) and increasing doses of paclitaxel (as a representative cytotoxic agent). Thumbnails
qualitatively display increasing ethidium bromide intercalation (red) and decreasing esterase activity (green) with increasing cytotoxic dose similar for all
therapies assayed here. Scale bars5 500 mm. In (b),mean fluorescence signals from full fields after rescaling (Equation 1) are shown for escalating doses of
paclitaxel, carboplatin, etoposide, and verteporfin PDT treatments (from left to right) in the upper plots used to quantify overall viability (lower plots,
from Equation 2) and estimate fractional lethal doses (LD). In (c), distributions of nodule viabilities (N. 1000) from automated segmentation (shown
for paclitaxel-treated cultures) shifts to the left as expected with increasing dose. In (d), paclitaxel and carboplatin viability distributions at LD80
(thumbnails, left, scalebars5 500 mm) are juxtaposed to reveal a relatively tight distribution in the former in contrast to heterogeneous viability spectrum
in the latter with sub-populations up to 80–90% viable.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 3751 | DOI: 10.1038/srep03751 4
Figure 3 | Size heterogeneity in vitro and in vivo and size-dependent therapeutic response. (a): In vivo nodule size heterogeneity from representative
fluorescent microendoscope fields of xenograft implanatation of ovarian cancer cells, which resembles size distribution of the same cells grown in vitro.
Endoscope fields are 800 mm in diameter. (b): A representation of our use of segmentation in 3D culture image data to identify individual nodules from
the brightfield channel to generate a mask for computation of multiple readouts (shown in truncated form) for each individual nodule. In (c), viability-
volume scatter plots output by qVISTA code showing the rescaled viability of each nodule with respect to its volume, for thousands of nodules in each
treatment group, for each treatment. The vertical spread reflects dose response heterogeneity and for given a range of sizes. Probing size-dependent
response in thismanner reveals, for example, that the only nodules that are completely responsive to carboplatin are the smallest volume nodules while the
largest remainweakly viable even at a 1000 mM(LD80) dose. Response to paclitaxel is themost homogeneous and size-independent of therapies evaluated.
Etoposide-treated cultures exhibit a broad spread of viabilities over a broad spread of nodule sizes, while verteporfin-PDT treatment induces a
pronounced bi-modal response with simultaneously emergent populations of small nodules (1–10 cells) that are almost completely viable and almost
completely non-viable.
www.nature.com/scientificreports
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treated, relative to untreated, cultures. As seen in immunofluore-
scence images (Figure 4d) there is a clear contrast between strong
E-cadherin staining at cell junctions in untreated nodules, with
disrupted punctate intracellular E-cadherin staining in PDT-
treated nodules, consistent with the observation of disruption and
decreased cell-cell contact.
Quantification of growth inhibitory and cytotoxic treatment
effects. To examine a scenario in which it is useful to differentiate
cytotoxic from growth-inhibitory effects, we studied the contrasting
response of 3D pancreatic tumour nodules to gemcitabine and
paclitaxel. Visualization of gemcitabine response from microscope
fields stained with vital dyes (Figure 5a) shows that there is little or no
Figure 4 | Contrasting quantitative reporters of cytotoxic and structural response. In (a) high-resolution 3D confocal renderings of single nodules from
no treatment, carboplatin and verteporfin-PDT are shown from top to bottom to provide qualitative assessment of contrasting patterns of cytotoxic
response. Scale bars 5 50 mm. In (b), log-normal bi-modal nodule volume distributions show contrasting patterns between with little evidence of
disruption (upper plots, given doses of etoposide and carboplatin) and treatments which with appropriate dosage appear to have a propensity to
‘‘unpack’’ multicellular nodules (lower plots, paclitaxel and PDT). Each histogram contains statistics on 1,000–3,000micronodules. In the latter category
there is a shift in the bimodal size distribution from the proportion of nodules in the mode corresponding to larger sizes to smaller sizes consistent with
larger nodules being induced to disaggregate into an increased number of small nodules. In (c), disruption fraction, (Dfrac) based on the treatment-
induced shifts in size from (B), is reported with respect to the degree of lethality for several dose for each treatment tested. Error bars show standard error.
Verteporfin-PDT induces high Dfrac at low lethality while carboplatin and etoposide treatments suppresses viability at very high doses with negligible
architectural disruption. Paclitaxel also unpacks nodules but requires higher level of cell killing in order to do so. In (d), immunofluorescence images
show a clear contrast between strong E-cadherin staining at cadherens junctions in untreated nodules, with disrupted and punctate intracellular staining
in PDT-treated nodules, consistent with the observation of cellular disassociation.
www.nature.com/scientificreports
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evidence of cell death, even at high concentrations. This is reflected in
a nearly flat dose response curve as reported by the intensity-based
viability metric (Figure 5c). However, summation of the estimated
total volume of residual viable nodules overlaid on the same plot
(Figure 5b) reveals that there is a modest inhibition of growth. In
pancreatic 3D cultures treated with paclitaxel, we see a pronounced
cytotoxic response reflected in the image data (Figure 5b) and re-
ported by both treatment response metrics (Figure 5d). The simi-
larity in paclitaxel response with ovarian 3D cultures (Figures 2 and
3) indicates that the insensitivity to gemcitabine at nearly 100 times
the monolayer LD50 dose40 is reflective of the contrasting action of
the therapy, rather than the disease model. A slight disagreement
between intensity-based and segmentation-based (volume) metrics
at high cytotoxic doses (,90% killing) reflects segmentation error in
processing images with such weak calcein signal relative to back-
ground. The intensity-based viability metric, based on ratiometric
scaling of two fluorescent signals is however in close agreement with
validation by trypan blue exclusion counts (Supplemental Figure 2)
even at these high doses, making it a more appropriate metric to
quantify the action of a highly cytotoxic agent such as paclitaxel.
Discussion
We introduce a robust methodology to provide rapid readouts of
multiple treatment assessment endpoints from 3D in vitro tumour
models. This system not only overcomes technical barriers con-
founding the use of standard colorimetric assays in this context,
but also provides a degree of information content not approached
by such assays. We demonstrate the value of new quantitative
descriptors of therapeutic response for five different oncology agents.
The therapeutics evaluated here, while primarily driving cell death
through apoptosis, do so through contrastingmolecularmechanisms
with, as shown in this study, markedly contrasting patterns of struc-
tural and size-dependent response, heterogeneous induction of cell
death and/or growth inhibition, as summarized in Table 1. The char-
acteristic fingerprints of therapeutic behavior summarized in ??? can
be plausibly connected with more general phenomena, such as drug
resistance and drug penetration and/or the collective behavior of
multicellular nodules exposed to a given stressor. For example, the
former is suggested by the profound heterogeneity observed in res-
ponse to etoposide treatment. Given this non-uniformity of res-
ponse, for an LD50 dose of this agent there are significant fractions
of nodules that remain completely viable while others that are com-
pletely killed. In contrast to paclitaxel for example, with a nearly
uniform suppression of viability, this suggests that eachmulticellular
nodule is 50% dead, consisting of nearly 50% dead cells (outer layers)
and 50% viable cells (an inner core). It is also worth noting that while
paclitaxel treatment can drive essentially all cells in culture to nearly
absolute zero esterase activity at high doses, cultures subject to car-
boplatin exhibit populations of cells that remain weakly esterase
positive even with extremely high dosage thus exhibiting a lower
viability plateau of approximately 10% (Figure 1b). This reduction
of metabolic activity concomitant with persistent survival could be a
manifestation of a reversible senescent state, as recently shown for
cisplatin treatment, a chemically analogous agent41. These quantitat-
ive insights are reported rapidly using the combination of 3D tumour
models, and high-content image analysis described here.
We introduce a metric, Dfrac, which quantifies the extent of dis-
ruption and fragmentation of multicellular nodules that results from
treatment with a particular agent. In contrasting the marked differ-
ence in nodular disruption relative to cytotoxicity for carboplatin and
verteporfin-based PDT treatments examined here, it is provocative
that this new quantitative vocabulary provides a basis to account for
the previously reported synergistic enhancement in carboplatin effi-
cacy when pre-treated with PDT19. The concept that this enhance-
ment results in part from an increase in carboplatin penetration
following pre-treatment with PDT is supported by the high degree
of nodular disruption induced by the latter. The poor penetration of
carboplatin into large multicellular nodules, perhaps resulting from
the inability to unpack, or disaggregate tumours, is further supported
by the observed size-dependent response of this agent reported
here37. Importantly, the ability to quantify these treatment-induced
changes suggests the ability to utilize this approach for predictive
identification of combination therapies. For example, therapies that
are identified to disrupt tumour architecture (high Dfrac) could be
indexed for combination with those that exhibit weak penetration
through tight cell junctions yet are otherwise effective. It is provoc-
ative that paclitaxel and carboplatin, which are used in combination
Figure 5 | Analysis of contrasting growth inhibitory and cytotoxic
responses in a 3D pancreatic tumour model. (a): Representative
thumbnails frommerged fluorescent images of cleaved calcein AM (green)
and intercalated ethidiumbromide (red) for pancreatic 3D cultures treated
with (from left to right) untreated, 0.01, 1.0 and 100 mMgemcitabine doses
showing minimal evidence of cell death (ethidium bromide staining).
(b): Analogous thumbnails for identical pancreatic 3D cultures (left to
right) untreated, or treated with 2.78, 11.1 or 44.5 mMpaclitaxel dosage. In
(c), estimation of tumour volumes reports a modest growth inhibition
(,20%) from gemcitabine treatment which is not detected by the
intensity-based viability metric. In (d), a strong cytotoxic response to
paclitaxel is reported by both metrics, with some disagreement from at
doses nearing 90% killing due to error in segmentation of weak calcein
signals in those treated cultures.
www.nature.com/scientificreports
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as first line therapy for management of advanced ovarian cancer32,
are revealed here to have inversely related structural effects. The
nearly equal and opposite levels of architectural disruption (where
Dfrac is negative for carboplatin) seen at an LD90 level for these two
agents indicates that the weakly viable micronodules left behind are
relatively small in one case, and relatively large in the other case. This
could contribute to a mechanistic explanation of how these agents in
combination could achieve a more complete response at safer doses.
The ability to make such correlations between structural and cyto-
toxic responses could be invaluable in screening and informing
rationally-designed combinations of the next generation of oncology
agents.
A critical component of the imaging-based strategy introduced
here is the rational tradeoff of image-acquisition parameters for field
of view, depth of field and optical resolution, and the development of
image processing routines for appropriate removal of background,
scaling of fluorescence signals from more than one channel and
reliable segmentation of nodules. In order to obtain depth-resolved
3D structures for each nodule at sub-micron lateral resolution using
a laser-scanning confocal system, it would require , 40 hours (at
approximately 100 fields for each well with a 203 objective, times
1 minute/field for a coarse z-stack, times 24 wells) to image a single
plate with the same coverage achieved in this study. Even if the
resources were available to devote to such time-intensive image
acquisition, not to mention the processing, the optical properties
of the fluorophores would change during the required time frame
for image acquisition, even with environmental controls to maintain
culture viability during such extended imaging. The approach
developed here, with amind toward adaptation into high throughput
screening, provides a rational balance of speed, requiring less than
30 minutes/plate, and statistical rigour, providing images of thou-
sands of nodules in this time, as required for the high-content ana-
lysis developed in this study. These parameters can be further
optimized for specific scenarios. For example, we obtain the same
number of images in a 96 well plate as for a 24 well plate by acquiring
only a single field from each well, rather than 4 stitched fields. This
quadruples the number conditions assayed in a single run, at the
expense of the number of nodules per condition, and therefore the
ability to obtain statistical data sets for size-dependent response,Dfrac
and other segmentation-dependent numerical readouts.
We envision that the system for high-content interrogation of
therapeutic response in 3D cell culture could havewidespread impact
in multiple arenas from basic research to large scale drug develop-
ment campaigns. As such, the treatment assessment methodology
presented here does not require extraordinary optical instrumenta-
tion or computational resources, making it widely accessible to any
research laboratory with an inverted fluorescence microscope and
modestly equipped personal computer. And although we have
focused here on cancer models, the methodology is broadly
applicable to quantitative evaluation of other tissue models in regen-
erative medicine and tissue engineering. While this analysis toolbox
could have impact in facilitating the implementation of in vitro 3D
models in preclinical treatment evaluation in smaller academic
laboratories, it could also be adopted as part of the screening pipeline
in large pharma settings. With the implementation of appropriate
temperature controls to handle basement membranes in current
robotic liquid handling systems, our analyses could be used in ultra
high-throughput screening. In addition to removing non-efficacious
potential candidate drugs earlier in the pipeline, this approach could
also yield the additional economic advantage of minimizing the use
of costly time-intensive animal models through better estimates of
dose range, sequence and schedule for combination regimens.
Methods
Three-dimensional cell culture. NIH:OVCAR-5 epithelial ovarian cancer cells were
obtained from Thomas Hamilton (Fox Chase Cancer Institute, Philadelphia, PA).
PANC-1 cells were obtained from American Type Culture Collection (ATCC,
Rockville, MD) andmaintained according to ATCC instructions. Cell media and fetal
bovine serum were obtained from Mediatech (Herndon, VA) and Invitrogen
(Carlsbad, CA), respectively. Cells were maintained in either RPMI-1640 medium
(OVCAR-5) or DMEM (PANC-1) supplemented with 10% heat-inactivated fetal calf
serum, 50 U/mL penicillin, and 50 mg/mL streptomycin. 3D cultures were prepared
in overlay geometry adapting a method previously described by Lee et al23. Briefly, a
1 mL volume of single cell suspension of 7,500 cells/mL in complete medium
containing 2% Growth Factor Reduced (GFR) Matrigel was overlaid on beds of GFR
Matrigel on glass-bottom 24-well plates (Greiner BioOne). GFR Matrigel beds were
initially prepared by ejecting 250 mL of Matrigel solution at,4uC on chilled culture
plates and carefully rotating at a slight angle to distribute evenly. This method forms a
bed that is approximately 500 mm thick near the center of the well where images were
obtained (the ECM bed is thicker near the edges due to a meniscus effect). Cultures
were then incubated at 37uC for 30 minutes prior to plating cells to allow gelation to
occur. For growth on 96 well plates, the cell count was scaled down to 1250 cells in
100 mLmedia to account for a growth area that is approximately one sixth that of a 24
well plate with a reduction in GFR Matrigel bed volume in the same ratio. Following
initial dispensing, cells were allowed to adhere to the Matrigel bed before addition of
complete growth medium containing 2% GFR Matrigel. As noted previously23, the
highly diluted 2% GFR Matrigel supplementing the complete growth medium in the
overlay does not form a gel, but does provide ECM signaling cues throughout culture
growth for cells not in physical contact with the underlying ECM bed. All cultures
were maintained in an incubator at 37uC in an atmosphere of 5% CO2.
Chemotherapy treatments. Chemotherapy treatments were performed by
incubating 3D cultures in growth medium with the indicated dosage of carboplatin
(NDC: 61703-360-22; NOVAPLUS, Irving, TX, USA) diluted to 5–2560 mM,
paclitaxel (NDC: 61703-342-22; Hospira Worldwide, Inc. Lake Forest, IL, USA),
etoposide (NDC: 0703-5653-01; Teva Pharmaceuticals, Irvine, CA, USA) diluted to
1–100 mM, or gemcitabine (NDC: 0781-3282-75; Eli Lily and Company,
Indianapolis, IN, USA) diluted to 0.01 to 1000 mM. Chemotherapy agents were
allowed to incubate for 72 hours with the exception of caroboplatin incubations
which were conducted for a total of 96 hours with a refresh at 48 hours. The
incubation times chosen for this study are consistent with previous reports and reflect
the observation that 3D tumor models typically require a longer period of drug
exposure relative to traditional monolayer cultures and these treatment schedules
more closely resemble in vivo therapeutic assessment scenarios19,40,42. All
chemotherapy drugs were clinical grade formulations purchased from the central
pharmacy at the Massachusetts General Hospital. Treatment response was assessed
immediately after removal of the chemotherapeutic agent.
Table 1 | Summary of multiple readouts from quantitative image-based therapeutic assessment comparing measured outcomes by drug
type and mechanism of action for 5 agents evaluated in this study
Classification qVISTA readouts
Agent Class
Relative Toxicity
(Clinical) Cytotoxicity
Growth
Inhibition Heterogeneity
Architectural
Disruption (Dfrac)
Carboplatin Alkylating agent (platinum) High High High Moderate Low
Etoposide Topoisomerase II inhibitor High Moderate High Moderate Low
Paclitaxel Microtubule disassembly inhibitor High High High Low High
Gemcitabine Nucleoside analog Low Low Moderate Low Low
PDT (verteporfin) Photochemistry-based modality High (Localized) High Moderate High High
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In vivo high-resolution fluorescence microendoscopy. For in vivo comparisons we
used a murine model of disseminated ovarian carcinoma previously established in
our laboratory38. Briefly, female Swiss nude mice (Cox, Cambridge, MA), 6–8 weeks
old, were injected intraperitoneally 3.153 107 OVCAR5 cells in single cell suspension
in 2 mL PBS. Tumours were allowed to develop for 14 days prior to imaging, during
which time mice had continual access to food and water while being housed in
laminar flow racks under specific pathogen-free conditions. Microendoscopy was
performed as previously described39, using intraperitoneal injection with 1 mg/kg
body weight of verteporfin (benzoporhyrin derivative monoacid ring-A or BPD-MA,
VWR, Radnor, PA, USA) for fluorescence contrast. Imaging was performed under
anesthesia with the fibre probe introduced into the intraperitoneal cavity via a
catheter inserted through the abdominal wall. Approximately 20 separate
microendoscope fields were obtained throughout the peritoneal cavity for each
mouse. Microendoscope images were segmented in the same manner as described
below for 3D cell cultures to obtain the distribution of tumour sizes throughout the
peritoneal cavity. All animal procedures were conducted in accordance with
institutional guidelines for research animal care.
Photodynamic therapy treatments. Cell cultures were incubated with medium
containing 1 mM verteporfin for 90 minutes prior to irradiation, at which time the
mediumwas replacedwith verteporfin-freemedium. Cells were irradiated at specified
doses using a 690 nm laser diode source (Model 7401; Intense, North Brunswick, NJ)
at a fluence rate of 150 mW/cm2 as measured via a VEGA laser power energy meter
(Ophir Laser Measurement Group, LLC) and then allowed to incubate for 24 hours
prior to evaluation of treatment response. Laser irradiation was delivered through the
bottom of each well via a vertically mounted Thorlabs multimode fiber (FT600EMT,
Thorlabs, Newton, NJ), collimated to overfill the dish area for nearly uniform light
delivery.
Confocal immunofluorescence imaging. Preparation of 3D culture for
immunofluorescence imaging was adapted from a procedure previously described by
Debnath et al43. Cultures were initially prepared in glass bottom 24 well plates as
described above, and grown for the specified duration prior to paraformaldehyde
fixation (2%) and permeabilization with 0.5% Triton X-100. The exchange of buffers
and staining solutions was accomplished using a micropipetter to minimize
disruption of the Matrigel. The anti-E-cadherin primary antibody used in this study
was conjugated directly to Alexa Fluor 488 (Cell Signaling, Danvers, MA, USA). After
incubation with antibody solution, cells were washed and covered with mounting
medium containing DAPI (Prolong Antifade with DAPI, Invitrogen, Carlsbad, CA)
to label nuclei. All confocal immunofluorescence images were obtained using a 403
water immersion objective, with pinhole open to 180 mm, on an Olympus FV-1000
confocal microscope (Olympus of America) and configured for simultaneous
imaging of DAPI and Alexa Fluor 488 fluorescence emission without spectral bleed
through or cross talk between channels.
Fluorescence Imaging. Live cultures were stained, in situ, with Calcein AM
(Invitrogen) and Ethidium Bromide (Sigma Aldrich) as fluorescent markers for live
and dead cells respectively, and returned to the incubator for 40 minutes prior to
imaging. For wells designated as total killing (TK) controls, the additional steps of
fixation and permeabilization were performed prior to addition of fluorescence
reagents, to establish control conditions formaximal ethidium bromide intercalation.
In this case, cultures were fixed and permeabilized as for samples prepared for
immunofluorescence (see above). No treatment (NT) groups within each batch were
grown and maintained identically to treated groups and subject to sham
manipulations prior to imaging-based evaluation at the same time as other treatment
groups. All images were obtained using an Olympus FV-1000 confocal microscope
using a 0.16NA 43 objective to obtain stitched multichannel mosaics of 4 5123 512
pixel image fields spanning 6.3 mm3 6.3 mm from the central region of each well.
Images were acquired in a de facto widefield limit, with the pinhole open to 600 um,
so as to allow for maximum integration of fluorescence emission over the z-
dimension of 3D objects without the high time cost of refocusing and acquiring stacks
at multiple z-positions for each spatial field during this time-sensitive procedure. The
488 nm line from an Argon ion laser and a 559 nm laser diode were used for
excitation of the converted calcein, imaged through a FITC emission filter and
intercalated ethidium bromide, imaged through a TRITC emission filter, respectively.
Saved images were grouped into a pre-assigned system of subdirectories for off-line
batch-processing in MATLAB.
qVISTA image processing routines. The ratiometric measure of overall mean
culture viability is obtained from spatially averaged intensities of calcein (CG, live)
and ethidium bromide (EtBr, dead) fluorescence signals (after background
subtraction) in image fields for each treatment group as shown in Equation 1:
Viability~
CG
CGzwEB
where, w~
CGNT{CGTK
EBTK{EBNT
ð1Þ
The subscripts NT and TK designate mean values for no-treatment (NT) and total-
killing (TK) controls. The scaling factor w rescales all values to internal non-treated
and total killing controls and corrects for inevitable variability in imaging parameters
andminor instrumentation drift across evaluation timepoints to provide quantitative
analysis that corrects for these parameters. This rescaling is critical to introduce
standardized intensity ‘‘units’’ that are compatible between two separate fluorescent
channels from two fluorophores, excited with different lasers, imaged through
separate optical filters. All fluorescence intensity measurements are obtained from
background corrected images, where the image histogram is automatically tabulated
to determine mean and mode intensity.
To generate plots of size-dependent treatment response from images containing
heterogeneous distributions of multicellular 3D micronodules, multi-resolution
wavelet decomposition44 of brightfield images was first used for gradient background
removal as shown in Supplemental Figure 1. In order to generate a mask for
subsequent processing, background-corrected images were segmented, using a built
in MATLAB routine based on an implementation of Otsu’s method, as previously
described for similar image data24. The volume of each individual segemented object
was calculated based on a best-fit ellipsoid of major and minor axis a and b
respectively (Equation 2). Other parameters, including eccentricity (second moment
estimate), centroid coordinates, and equivalent (circular) diameter are automatically
tabulated and reported for each nodule. The segmented image was also used to
generate a binary mask, which was multiplied by each fluorescent channel to obtain
viability for each masked region (each micronodule) using the same process for
rescaling and internally normalizing viabilities as described above. In this manner,
viability-volume scatter plots were generated. Additionally, the same segmentation
procedure was invoked on the esterase-cleaved calcein image channels for each
treatment group to obtain statistics on the size (volume) distribution of residual
calcein positive (viable) nodules or regions thereof. Summation over all nodule
volumes (Vn) in each group provides an estimate of fractional residual volume relative
to the NT group, VNT, which serves as an additional metric describing overall cyto-
toxic response:
Vn~
4
3
pab2, Vresidual~
P
n
Vn
VNT
ð2Þ
For quantification of architectural disruption in response to treatment we fit to the to
the previously reported bimodal lognormal size distribution that describes in vitro
nodule formation in the overlay geometry45 as shown in Equation 3:
fTOT s
0ð Þ~ A1
w1
ﬃﬃﬃﬃﬃﬃﬃﬃ
p=2
p e
{ s0{sc1ð Þ2
w1
2 z
A2
w2
ﬃﬃﬃﬃﬃﬃﬃﬃ
p=2
p e
{ s0{sc2ð Þ2
w2
2
~f1 s
0ð Þzf2 s0ð Þ where s0~ log2 s=100ð Þ
ð3Þ
Upon treatment the size distribution of residual viable disease may shift, (Figure 4) as
larger nodules into smaller fractions. To quantify this observation we introduce a
metric, disruption fraction (Dfrac) which reports the fractional shift from the larger
size mode (f2) to the smaller mode (f1) in size distributions relative to NT controls:
Dfrac~
Ð
ds0f Tx1 s
0ð Þ{ Ð ds0f NT1 s0ð Þ
1{
Ð
ds0f NT1 s0ð Þ
ð4Þ
In practice, for economy of computation speed, and to avoid instabilities from
repeated non-linear least squares curve fits, this calculation is performed as the
equivalent summation over discrete volume bins where a cutoff-bin is determined
based on the inflection point in the bimodal curve (corresponding to f1 5 f2).
Validation of cell viability measurements. For validation of the overall viability
metric introduced here, treatment response was also assessed by trypan blue
exclusion. Comparisons are provided with the substantial caveat that the lack of
suitable assays for assessment of 3D micronodules adherent to ECM, and challenges
of reliable nodule disaggregation are in fact motivating forces for developing an
imaging-based in situ assessment in the present study. In order to obtain reliable cell
counts, 3Dmicronodules from each treatment condition had to first be removed from
GFRMatrigel by 2 hour digestion with dispase (BD Biosciences, Bedford, MA, USA),
followed by an additional resuspension in 0.25% Trypsin EDTA (Mediatech,
Herndon, VA, USA) to disaggregate multicellular nodules. For cell counting
experiments, disaggregated cells were then stained with trypan blue before transfer to
a hemacytometer.
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